BR112017017700A2 - métodos, composições e kits para tratamento do câncer - Google Patents

métodos, composições e kits para tratamento do câncer

Info

Publication number
BR112017017700A2
BR112017017700A2 BR112017017700A BR112017017700A BR112017017700A2 BR 112017017700 A2 BR112017017700 A2 BR 112017017700A2 BR 112017017700 A BR112017017700 A BR 112017017700A BR 112017017700 A BR112017017700 A BR 112017017700A BR 112017017700 A2 BR112017017700 A2 BR 112017017700A2
Authority
BR
Brazil
Prior art keywords
kits
compositions
cancer treatment
treatment methods
gffr3
Prior art date
Application number
BR112017017700A
Other languages
English (en)
Inventor
Holash Jocelyn
Lau Stephen
Original Assignee
Bioclin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclin Therapeutics Inc filed Critical Bioclin Therapeutics Inc
Publication of BR112017017700A2 publication Critical patent/BR112017017700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

é aqui proporcionado o uso de inibidores de fgfr3 e inibidores de pd1 para tratar cânceres sólidos e hematológicos e composições e kits que compreendem um inibidor de fgfr3 e um inibidor de pd1.
BR112017017700A 2015-02-19 2016-02-19 métodos, composições e kits para tratamento do câncer BR112017017700A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118350P 2015-02-19 2015-02-19
US201562150235P 2015-04-20 2015-04-20
PCT/US2016/018634 WO2016134234A1 (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer

Publications (1)

Publication Number Publication Date
BR112017017700A2 true BR112017017700A2 (pt) 2018-07-31

Family

ID=56689191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017700A BR112017017700A2 (pt) 2015-02-19 2016-02-19 métodos, composições e kits para tratamento do câncer

Country Status (12)

Country Link
US (1) US20160243228A1 (pt)
EP (1) EP3258966A4 (pt)
JP (2) JP6774421B2 (pt)
KR (1) KR20170137717A (pt)
CN (1) CN107635583A (pt)
AU (2) AU2016219917B2 (pt)
BR (1) BR112017017700A2 (pt)
CA (1) CA2976638A1 (pt)
IL (1) IL253979B (pt)
MX (1) MX2017010595A (pt)
SG (1) SG11201706727XA (pt)
WO (1) WO2016134234A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3702371T3 (da) 2009-03-25 2022-11-28 Genentech Inc Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
LT3122359T (lt) 2014-03-26 2021-03-25 Astex Therapeutics Ltd. Fgfr inhibitoriaus ir igf1r inhibitoriaus deriniai
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
ES2811845T3 (es) 2015-09-23 2021-03-15 Janssen Pharmaceutica Nv Heterociclos tricíclicos para el tratamiento del cáncer
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
WO2018145120A1 (en) * 2017-02-06 2018-08-09 Bioclin Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer
CN108440673B (zh) * 2018-04-08 2021-08-17 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
KR20220016803A (ko) * 2019-06-03 2022-02-10 퓨전 파마슈티칼즈 인크. 암을 치료하기 위한 방법 및 조성물
AU2020352668A1 (en) * 2019-09-26 2022-03-31 Janssen Pharmaceutica Nv Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
WO2022092085A1 (ja) * 2020-10-28 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
DK3702371T3 (da) * 2009-03-25 2022-11-28 Genentech Inc Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
US8754114B2 (en) * 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2878183A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
KR20160030936A (ko) * 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법

Also Published As

Publication number Publication date
IL253979B (en) 2021-06-30
KR20170137717A (ko) 2017-12-13
US20160243228A1 (en) 2016-08-25
JP6774421B2 (ja) 2020-10-21
CA2976638A1 (en) 2016-08-25
WO2016134234A1 (en) 2016-08-25
JP7122357B2 (ja) 2022-08-19
IL253979A0 (en) 2017-10-31
AU2016219917A1 (en) 2017-09-07
CN107635583A (zh) 2018-01-26
JP2021020909A (ja) 2021-02-18
EP3258966A1 (en) 2017-12-27
SG11201706727XA (en) 2017-09-28
AU2016219917B2 (en) 2021-12-16
AU2022200196A1 (en) 2022-02-10
MX2017010595A (es) 2018-11-12
JP2018507220A (ja) 2018-03-15
EP3258966A4 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
ES2975183T3 (es) Inhibidores de ENPP1 y su uso para el tratamiento del cáncer
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
DK3416956T3 (da) Methylaminderivater som lysyloxidasehæmmere til cancerbehandling
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112016022667A2 (pt) Uso de álcool d-pantotenílico para a fabricação de inibidor de melanogênese e método de branquear a pele
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CL2018003417A1 (es) Nuevos compuestos.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
CL2016002948A1 (es) Uso de compuestos inhibidores de proteasoma que contienen boro, para el tratamiento de cáncer.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIOCLIN THERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: BIOCLIN THERAPEUTICS, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870200115552 DE 11/09/2020, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO E O NOME DA EMPRESA CEDENTE.

B25D Requested change of name of applicant approved

Owner name: RAINIER THERAPEUTICS, INC. (US)

B25A Requested transfer of rights approved

Owner name: FUSION PHARMACEUTICALS INC. (CA)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]